Kezar (KZR) is discontinuing development of its drug zetomipzomib for the treatment of lupus nephritis so it can focus on ...
Kezar Life Sciences announced the termination of Phase 2b PALIZADE clinical trial of zetomipzomib, an investigational therapy ...
On Thursday, Kezar Life Sciences, Inc (NASDAQ:KZR) decided to terminate the PALIZADE Phase 2b trial in patients with active ...
GlobalData on MSN4d
Kezar Life Sciences discontinues lupus nephritis programme after fatalitiesKezar’s decision to terminate the PALIZADE IIb trial comes after it was placed on a clinical hold due to four patient deaths.
The regulator's decision came after the company paused the study in September to review safety data following the deaths of ...
The IDMC overseeing the PORTOLA Phase 2a clinical trial of zetomipzomib in patients with AIH recommended that the trial may proceed without modification following its third scheduled meeting.
Kezar’s own plans were knocked off course in recent weeks when the company paused a phase 2 trial of its selective immunoproteasome inhibitor zetomipzomib in lupus nephritis in relation to the ...
Last week, the FDA placed a clinical hold on the company’s zetomipzomib Investigational New Drug (IND) application for LN following a review of emerging safety data, including an assessment of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback